|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBM4 |
Gene summary for RBM4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBM4 | Gene ID | 5936 |
| Gene name | RNA binding motif protein 4 | |
| Gene Alias | LARK | |
| Cytomap | 11q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9BWF3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5936 | RBM4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.39e-04 | 2.59e-01 | 0.0155 |
| 5936 | RBM4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.64e-12 | 6.76e-01 | -0.1808 |
| 5936 | RBM4 | HTA11_2951_2000001011 | Human | Colorectum | AD | 9.28e-03 | 6.44e-01 | 0.0216 |
| 5936 | RBM4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.51e-14 | 7.49e-01 | -0.0811 |
| 5936 | RBM4 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.11e-12 | 5.29e-01 | -0.1954 |
| 5936 | RBM4 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.87e-03 | 5.78e-01 | -0.2196 |
| 5936 | RBM4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.02e-04 | 6.38e-01 | -0.1207 |
| 5936 | RBM4 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.69e-21 | 6.31e-01 | -0.1464 |
| 5936 | RBM4 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.98e-03 | 3.49e-01 | -0.1001 |
| 5936 | RBM4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.19e-14 | 8.07e-01 | -0.059 |
| 5936 | RBM4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.20e-04 | 5.90e-01 | -0.2061 |
| 5936 | RBM4 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.21e-02 | 3.68e-01 | -0.0842 |
| 5936 | RBM4 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.83e-16 | 6.80e-01 | 0.096 |
| 5936 | RBM4 | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.41e-02 | 6.79e-01 | 0.0446 |
| 5936 | RBM4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.20e-04 | 4.29e-01 | 0.0528 |
| 5936 | RBM4 | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.32e-05 | 7.58e-01 | 0.0131 |
| 5936 | RBM4 | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.88e-06 | 5.81e-01 | -0.0177 |
| 5936 | RBM4 | HTA11_6801_2000001011 | Human | Colorectum | SER | 8.45e-03 | 6.59e-01 | 0.0171 |
| 5936 | RBM4 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.84e-04 | 4.36e-01 | 0.0338 |
| 5936 | RBM4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.86e-08 | 4.97e-01 | 0.0674 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00466857 | Prostate | BPH | response to arsenic-containing substance | 17/3107 | 33/18723 | 4.14e-06 | 6.25e-05 | 17 |
| GO:00171484 | Prostate | BPH | negative regulation of translation | 68/3107 | 245/18723 | 7.01e-06 | 1.01e-04 | 68 |
| GO:00459473 | Prostate | BPH | negative regulation of translational initiation | 11/3107 | 19/18723 | 5.28e-05 | 5.42e-04 | 11 |
| GO:00427528 | Prostate | BPH | regulation of circadian rhythm | 37/3107 | 121/18723 | 9.71e-05 | 9.04e-04 | 37 |
| GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
| GO:00022444 | Prostate | BPH | hematopoietic progenitor cell differentiation | 34/3107 | 114/18723 | 3.08e-04 | 2.37e-03 | 34 |
| GO:00426926 | Prostate | BPH | muscle cell differentiation | 88/3107 | 384/18723 | 7.59e-04 | 5.01e-03 | 88 |
| GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
| GO:000641317 | Prostate | Tumor | translational initiation | 66/3246 | 118/18723 | 2.57e-21 | 2.66e-18 | 66 |
| GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
| GO:000641719 | Prostate | Tumor | regulation of translation | 161/3246 | 468/18723 | 1.55e-19 | 8.74e-17 | 161 |
| GO:190331117 | Prostate | Tumor | regulation of mRNA metabolic process | 111/3246 | 288/18723 | 6.66e-18 | 2.30e-15 | 111 |
| GO:004348419 | Prostate | Tumor | regulation of RNA splicing | 70/3246 | 148/18723 | 3.22e-17 | 1.05e-14 | 70 |
| GO:000037518 | Prostate | Tumor | RNA splicing, via transesterification reactions | 119/3246 | 324/18723 | 3.40e-17 | 1.06e-14 | 119 |
| GO:000037718 | Prostate | Tumor | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
| GO:000039818 | Prostate | Tumor | mRNA splicing, via spliceosome | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
| GO:005068416 | Prostate | Tumor | regulation of mRNA processing | 64/3246 | 137/18723 | 1.55e-15 | 2.75e-13 | 64 |
| GO:000644615 | Prostate | Tumor | regulation of translational initiation | 44/3246 | 79/18723 | 1.37e-14 | 1.89e-12 | 44 |
| GO:004802419 | Prostate | Tumor | regulation of mRNA splicing, via spliceosome | 51/3246 | 101/18723 | 2.29e-14 | 2.97e-12 | 51 |
| GO:000218317 | Prostate | Tumor | cytoplasmic translational initiation | 25/3246 | 34/18723 | 8.99e-13 | 8.73e-11 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBM4 | SNV | Missense_Mutation | c.477G>C | p.Gln159His | p.Q159H | Q9BWF3 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RBM4 | SNV | Missense_Mutation | rs771127066 | c.1079N>A | p.Arg360Gln | p.R360Q | Q9BWF3 | protein_coding | tolerated(0.09) | probably_damaging(0.968) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| RBM4 | SNV | Missense_Mutation | c.286N>A | p.Ala96Thr | p.A96T | Q9BWF3 | protein_coding | tolerated(0.09) | benign(0.292) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RBM4 | insertion | Frame_Shift_Ins | novel | c.751_752insT | p.Gln251LeufsTer24 | p.Q251Lfs*24 | Q9BWF3 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| RBM4 | insertion | Frame_Shift_Ins | novel | c.753_754insATGTCCTCTTCCCTCTTGCCATCGTG | p.Leu252MetfsTer125 | p.L252Mfs*125 | Q9BWF3 | protein_coding | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR | ||
| RBM4 | SNV | Missense_Mutation | rs752990000 | c.721G>A | p.Val241Met | p.V241M | Q9BWF3 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-C5-A1ML-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| RBM4 | SNV | Missense_Mutation | c.359G>A | p.Arg120Gln | p.R120Q | Q9BWF3 | protein_coding | tolerated(0.07) | benign(0.124) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| RBM4 | SNV | Missense_Mutation | rs765301901 | c.158N>A | p.Arg53His | p.R53H | Q9BWF3 | protein_coding | tolerated(0.1) | benign(0.075) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBM4 | SNV | Missense_Mutation | c.245N>C | p.Val82Ala | p.V82A | Q9BWF3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| RBM4 | SNV | Missense_Mutation | c.1046N>A | p.Arg349Gln | p.R349Q | Q9BWF3 | protein_coding | deleterious(0.02) | benign(0.174) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |